Show simple item record

dc.contributor.authorJentes, Emily S.
dc.contributor.authorHan, Pauline
dc.contributor.authorGershman, Mark D.
dc.contributor.authorRao, Sowmya R.
dc.contributor.authorLaRocque, Regina C.
dc.contributor.authorStaples, J. Erin
dc.contributor.authorRyan, Edward T.
dc.date2022-08-11T08:10:34.000
dc.date.accessioned2022-08-23T17:12:58Z
dc.date.available2022-08-23T17:12:58Z
dc.date.issued2013-03-04
dc.date.submitted2013-04-10
dc.identifier.citationAm J Trop Med Hyg. 2013 Mar 4. <a href="http://dx.doi.org/10.4269/ajtmh.12-0463">Link to article on publisher's site</a>
dc.identifier.issn0002-9637 (Linking)
dc.identifier.doi10.4269/ajtmh.12-0463
dc.identifier.pmid23458961
dc.identifier.urihttp://hdl.handle.net/20.500.14038/46620
dc.description.abstractYellow fever (YF) vaccine-associated serious adverse events and changing YF epidemiology have challenged healthcare providers to vaccinate only travelers whose risk of YF during travel is greater than their risk of adverse events. We describe the travel characteristics and YF vaccine use among US travelers visiting Global TravEpiNet clinics from January of 2009 to March of 2011. Of 16,660 travelers, 5,588 (34%) had itineraries to areas with risk of YF virus transmission. Of those travelers visiting one country with YF risk (N = 4,517), 71% were vaccinated at the visit, and 20% were presumed to be immune from prior vaccination. However, travelers visiting friends and relatives (odds ratio [OR] = 2.57, 95% confidence interval [95% CI] = 1.27-5.22) or going to Nigeria (OR = 3.01, 95% CI = 1.37-6.62) were significantly more likely to decline vaccination. To optimize YF vaccine use, clinicians should discuss an individual's risk-benefit assessment of vaccination and close knowledge gaps regarding vaccine use among at-risk populations.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23458961&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.4269/ajtmh.12-0463
dc.subjectClinical Epidemiology
dc.subjectHealth Services Research
dc.subjectInternational Public Health
dc.subjectVirus Diseases
dc.titleTravel Characteristics and Yellow Fever Vaccine Usage Among US Global TravEpiNet Travelers Visiting Countries with Risk of Yellow Fever Virus Transmission, 2009-2011
dc.typeJournal Article
dc.source.journaltitleThe American journal of tropical medicine and hygiene
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/qhs_pp/1082
dc.identifier.contextkey4020085
html.description.abstract<p>Yellow fever (YF) vaccine-associated serious adverse events and changing YF epidemiology have challenged healthcare providers to vaccinate only travelers whose risk of YF during travel is greater than their risk of adverse events. We describe the travel characteristics and YF vaccine use among US travelers visiting Global TravEpiNet clinics from January of 2009 to March of 2011. Of 16,660 travelers, 5,588 (34%) had itineraries to areas with risk of YF virus transmission. Of those travelers visiting one country with YF risk (N = 4,517), 71% were vaccinated at the visit, and 20% were presumed to be immune from prior vaccination. However, travelers visiting friends and relatives (odds ratio [OR] = 2.57, 95% confidence interval [95% CI] = 1.27-5.22) or going to Nigeria (OR = 3.01, 95% CI = 1.37-6.62) were significantly more likely to decline vaccination. To optimize YF vaccine use, clinicians should discuss an individual's risk-benefit assessment of vaccination and close knowledge gaps regarding vaccine use among at-risk populations.</p>
dc.identifier.submissionpathqhs_pp/1082
dc.contributor.departmentDepartment of Quantitative Health Sciences


This item appears in the following Collection(s)

Show simple item record